ClinicalTrials.gg
Active, not recruitingNCT07841210Updated Sep 25, 2026

Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors

A Phase 2 interventional study of Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine and Fosrolapitant and Palonosetron; Dexamethasone in Solid Tumor Cancer, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 2, Interventional, and Prevention

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by highly emetogenic antibody-drug conjugate (ADC) therapy in patients with solid tumors. A total of 60 patients are planned to be enrolled and divided into two groups: Group A will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone plus Olanzapine, and Group B will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone.

Read the detailed description

Antibody-drug conjugates (ADCs) have brought hope to cancer patients. For ADCs, nausea and vomiting are common adverse reactions. Compared with traditional chemotherapy, ADC-induced nausea and vomiting are usually more complex, with a higher risk of delayed nausea and vomiting. For example, trastuzumab deruxtecan, a HER2-targeted ADC, has a median time to onset of vomiting of 9.5 days and a median duration of 3 days, and a median time to onset of nausea of 3 days and a median duration of up to 10 days. Sacituzumab govitecan, a Trop-2-targeted ADC, has a median time to onset of vomiting of 24.5 days and a median duration of 1.5 days, and a median time to onset of nausea of 8 days and a median duration of 5.5 days. Fosrolapitant and Palonosetron Hydrochloride for Injection, an innovative fixed-dose combination antiemetic, was approved for marketing by the Center for Drug Evaluation (CDE) on May 27, 2025. The half-life of fosrolapitant in Fosrolapitant and Palonosetron Hydrochloride for Injection is as long as 188 h, which can cover the acute, delayed, and ultra-delayed phases (120-168 h) of anti-tumor treatment-induced nausea and vomiting. This study intends to use Fosrolapitant and Palonosetron Hydrochloride for Injection as the basis combined with dexamethasone ± olanzapine to explore its efficacy and safety in preventing nausea and vomiting caused by highly emetogenic ADCs, and also to observe the preventive effect of other standard treatment (fosaprepitant + palonosetron + dexamethasone) on nausea and vomiting caused by highly emetogenic ADCs. It also aims to identify signals for the optimal management model of highly emetogenic ADC-related nausea and vomiting, so as to better guide clinical practice.

02

Conditions studied

  • Solid Tumor Cancer

Keywords

  • Fosrolapitant and Palonosetron Hydrochloride for Injection
  • ADC
  • CINV
03

In context

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, either sex;
  2. confirmed malignant solid tumors;
  3. Planned to receive initial highly emetogenic ADC therapy on a 3-week regimen;
  4. Expected survival ≥3 months;
  5. (ECOG) performance status score of 0 or 1;
  6. Adequate organ function, meeting the following criteria:

    1. ≥1.5 × 10⁹/L;
    2. ≥90 g/L;
    3. count ≥100 × 10⁹/L;
    4. Total ≤1.5 × ;
    5. In patients without known liver , ≤2.5 × ULN and/or alanine aminotransferase ≤2.5 × ULN (for patients with liver metastases, this may be relaxed to ≤5 × ULN);
    6. Serum creatinine ≤1.5 × ULN or ≥50 mL/min;
    7. : ≤450 ms (male), QTc ≤470 ms (female);
    8. Echocardiography: (LVEF) ≥50%;
  7. Female subjects of , and male subjects whose partners are women of childbearing potential, must use a highly effective method of from the signing of the form until 35 days after the last dose; sperm donation is not permitted during the study. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 h before randomization and must be non-lactating. Subjects must clearly understand and voluntarily participate in this study and personally sign the informed consent form.

Exclusion criteria

Exclusion Criteria

  1. Received, within 7 days before randomization, or planned to receive during the treatment period, abdominal radiotherapy (including at or below the diaphragmatic plane), pelvic radiotherapy, whole-body radiotherapy, or whole-brain radiotherapy;
  2. Planned to receive highly emetogenic chemotherapy from Day 2 after ADC administration until the next treatment;
  3. Prior use of other ADC drugs;
  4. Use of medications with potential antiemetic efficacy within 2 days before the start of study treatment: first-generation 5-HT3 receptor antagonists (e.g., ondansetron), phenothiazines (e.g., prochlorperazine), butyrophenones (e.g., haloperidol), benzamides (e.g., metoclopramide), domperidone, cannabinoids, traditional Chinese medicines with potential antiemetic effects, scopolamine, cyclizine, etc.;
  5. Initiation of benzodiazepines or opioids within 2 days before the start of study treatment (except triazolam, temazepam, or midazolam administered alone daily);
  6. Initiation of morphine within 7 days before the start of study treatment (except those receiving a stable dose);
  7. Receipt of systemic therapy (including but not limited to dexamethasone, hydrocortisone, methylprednisolone, or prednisolone) or sedating antihistamines (e.g., diphenhydramine) within 7 days before the start of study treatment (Note: single-dose steroids for prevention of contrast allergy and topical or inhaled administration are permitted);
  8. Use of palonosetron within 14 days before the start of study treatment;
  9. Use of NK-1 receptor antagonists within 28 days before the start of study treatment;
  10. Use of specific substrates (terfenadine, cisapride, astemizole) or CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, ketoconazole or itraconazole, diltiazem, etc.) within 7 days before the start of study treatment, or use of strong CYP3A4 inducers (e.g., phenobarbital, rifampin, phenytoin, carbamazepine, etc.) or specific CYP2D6 substrates (thioridazine, pimozide) within 28 days before randomization;
  11. Vomiting and/or retching, or nausea, within 24 h before the start of study treatment;
  12. Symptomatic or any symptoms suggestive of brain metastases or intracranial hypertension;
  13. Inadequately controlled serous cavity effusion, including pleural effusion, ascites, and pericardial effusion (those controlled after treatment and stable for ≥2 weeks may be enrolled);
  14. Severe cardiovascular disease within 3 months before the start of study treatment, including but not limited to acute myocardial infarction, unstable angina, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic chronic heart failure ( [NYHA] class II-IV), or history of serious cardiac conduction abnormalities (e.g., torsades de pointes);
  15. Poorly controlled hypertension before the start of study treatment (two consecutive resting systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);
  16. Active (HBV DNA ≥2000 IU/mL or 10⁴ copies/mL), active (HCV-Ab positive and HCV-RNA ≥ ), acquired immunodeficiency syndrome (AIDS) or -positive, or syphilis-positive;
  17. Concomitant disease that precludes dexamethasone administration, such as active infection (e.g., pneumonia) or any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction, etc.);
  18. Known to NK-1 receptor antagonists, 5-HT3 receptor antagonists, or dexamethasone;
  19. Participation in another clinical trial within 30 days before the start of study treatment (based on use of study drug);
  20. Other circumstances considered by the investigator to make participation in this study inappropriate.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group A:Fosrolapitant and Palonosetron + Dexamethasone + Olanzapine

    Drug: Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine

  • Experimental
    Group B:Fosrolapitant and Palonosetron + Dexamethasone

    Drug: Fosrolapitant and Palonosetron; Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving complete response (CR) during Days 0-21 after study drug administration in Cycle 1 (defined as no emetic episodes and no rescue medication use).

    Proportion of subjects achieving complete response (CR) during Days 0-21 after study drug administration in Cycle 1 (defined as no emetic episodes and no rescue medication use). Analysis of the primary study endpoint will be based on the intent-to-treat (ITT) population. The proportion of subjects achieving complete response (CR) during Days 0-21 after initiation of ADC administration in the first treatment cycle will be calculated for both groups. Descriptive between-group analysis of CR rates will be performed using the Cochran-Mantel-Haenszel (CMH) test.

    Time frame: Day 0-21 after first treatment cycle 1 dosing

Secondary outcomes

  1. The proportions of subjects with CR, no significant nausea, no nausea, no vomiting, no rescue medication use, complete protection, and complete control during the period.

    The proportions of subjects with complete response (CR), no significant nausea, no nausea, no vomiting, no rescue medication use, complete protection, and complete control during the acute phase (0-24 h after initiation of antitumor treatment), delayed phase (24-120 h after initiation of antitumor treatment), overall phase (0-120 h after initiation of antitumor treatment), super-delayed phase (120-168 h after initiation of antitumor treatment), 0-168 h, 120 h to the next treatment, and Days 0-21 in each treatment cycle.

    Time frame: After initiation of antitumor treatment:Acute: 0-24 hour; Delayed: 24-120 hours; Overall: 0-120 hours; Ultra-delayed: 120-168 hours;0 - 168 hours, 120 hours - next treatment and for the 2nd and subsequent treatment cycles 0 - 21 days

  2. Time to treatment failure

    Time to treatment failure in each cycle.

    Time frame: up to 4 cycles (each cycle is 21 days)

  3. The proportions of subjects with nausea and vomiting reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0

    Patient-reported outcomes (PROs): nausea and vomiting reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0;

    Time frame: up to 4 cycles (each cycle is 21 days)

  4. The proportions of subjects with Functional Living Index-Emesis (FLIE) assessment.

    Functional Living Index-Emesis (FLIE) assessment.

    Time frame: up to 4 cycles (each cycle is 21 days)

Other outcomes

  1. Incidence of adverse events and serious adverse reactions during treatment.

    Safety Evaluation

    Time frame: The treatment period will be observed for up to 4 cycles (each cycle is 21 days).

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 25, 2026
StartActual
Sep 14, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07841210
Collaborators
Nanyang Central Hospital, Hubei Cancer Hospital
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
Sep 14, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Sep 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fosrolapitant · Palonosetron · Dexamethasone · Olanzapine

Start the discussion